To study the staging accuracy of multiparametric magnetic resonance imaging (MRI) in patients showing unilateral low-risk cancer on prostate biopsy. A total of 58 consecutive patients with lowrisk cancer (D'Amico classification) and unilateral cancer involvement on prostate biopsies were included prospectively. All patients underwent multiparametric endorectal MRI before radical prostatectomy, including T2-weighted (T2W), diffusion-weighted (DW) and dynamic contrast enhanced (DCE) sequences. Each gland was divided in eight octants. Tumor foci 40.2 cm 3 identified on pathological analysis were matched with MRI findings. Pathological examination showed tumor foci 40.2 cm 3 in 50/58 glands (86%), and bilateral tumor (pathological stageXpT2c) in 20/58 (34%). For tumor detection in the peripheral zone (PZ), T2W þ DWI þ DCE performed significantly better than T2W þ DWI and T2W alone (Po0.001). In the transition zone (TZ), only T2W þ DWI performed better than T2W alone (P ¼ 0.02). With optimal MR combinations, tumor size was correctly estimated in 77% of tumor foci involving more than one octant. Bilateral tumors were detected in 80% (16/20) of cases. In patients with unilateral low-risk prostate cancer on biopsy, multiparametric MRI can help to predict bilateral involvement. Multiparametric MRI may therefore have a prognostic value and help to determine optimal treatment in such patients.
Introduction
With the widespread use of PSA screening, small and well-differentiated prostate cancers are increasingly being detected. 1 Up to one third have an index tumor volume o0.5 cm 3 and a Gleason score o7, and are more likely to remain latent. Considered as clinically insignificant or indolent, 2, 3 these cancers may be managed with active surveillance or with partial prostate ablation. However, validated criteria for identifying these patients have not been established yet. Correlation analyses have shown that patients with a predicted insignificant cancer at biopsy frequently showed tumors with more advanced stage and grade at radical prostatectomy (RP) pathological examination. 4 Attempts of thorough pathological mapping of the prostate have been made with saturation transrectal and transperineal prostate biopsies. 5 However, even these procedures might miss up to 40% of cancer foci.
Prostate magnetic resonance imaging (MRI) has undergone several technical improvements and shows promises for prostate tumor detection and localization. 6, 7 In addition to morphological information, MRI allows an estimation of physiological properties of tissues. Diffusion-weighted (DW) MRI is sensitive to restriction of diffusion of water molecules, and dynamic contrast enhanced (DCE) MRI can analyze tissue microvascular properties. 8 Multiparametric MRI combining DW images (DWI) and DCE has demonstrated its value in distinguishing malignant from benign prostate tissue. 9 However, most of the studies on multiparametric MRI have not specifically focused on low D'Amico risk patients, who are the potential candidates for less aggressive treatment strategies such as active surveillance, brachytherapy or focal ablation. The aims of this study were to evaluate which MR combination would be optimal for cancer detection, and to assess the incremental staging accuracy of multiparametric MRI in patients with suspected unilateral low-risk prostate cancer.
Patients and methods

Patient inclusion
Between October 2009 and May 2010, we included prospectively all consecutive patients with localized prostate cancer, unilateral cancer involvement on 12 core biopsy, with no more than two contiguous sextants involved, no core with cancer length 47 mm, a total cancer length p10 mm, and a low D'Amico risk (PSA level less than 10 ng ml À1 , Gleason score 6 and less than 33% positive biopsies). 10 All these patients underwent endorectal MRI examination before RP. MRI was performed at least 6 weeks after biopsies. A total of 58 patients were included. Median age was 62 years (49-74) and mean PSA level was 6.8 ng ml À1 (4-9.9). The study was approved by the institutional review board that issued a waiver of informed consent for review of the MRI and clinical data.
MRI
MR images were obtained using two 1.5T scanners with integrated endorectal and pelvic phased-array coils. The endorectal coil was inserted and inflated with air to a volume of B80-100 ml. The 3D-T2-weighted fast spin-echo sequence repetition time (TR)/echo time (TE): 1300/120 ms, voxel size: 0.8 Â 0.8 Â 1 mm, FOV: 20 Â 20 cm, acquisition time 5 min) covered the whole pelvis up to the aorta bifurcation (224 1-mm thick slices). DWI were obtained by using single-shot spin-echo echo-planar imaging (TR/TE: 3700/104 ms, voxel size 1.27 Â 1.27 Â 3.5 mm, 20 slices, acquisition time 4 min). Two b values (0-800) were used and the restriction of diffusion was quantified by the apparent diffusion coefficient (ADC) mapping. The image orientation and location was set to match the transverse T2-weighted (T2W) images. The 3D gradient echo DCE sequence was obtained with bolus injection of Gadolinium (0.1 mmol kg À1 at 3cc/sec followed by 15 ml saline flush, TR/TE/Flip Angle 5.11/1.85/101, voxel size 1.4 Â 1.4 Â 3.5 mm, FOV 20 Â 20 cm). The temporal resolution was of 8.5 s/phase over 5 min. DCE images were postprocessed with a pharmacokinetic analysis model, based on Tofts. 11 Weinmann's arterial input function model 12 was used to estimate tissue physiological parameters: K trans (transfer constant), k ep (rate constant). The initial area under the gadolinium concentration curve for the first 60 s after contrast arrival was also calculated.
MRI prostate mapping and evaluation of data
Two experienced radiologists (FC and DE) interpreted the MR images by consensus. The readers were blinded to clinical, biological and pathological results. They were only aware that the patients had prostate cancer. Both the peripheral zone (PZ) and the transition zone (TZ) of each prostate were divided into four quadrants, resulting in eight octants per prostate and 464 areas for the whole study. The separation between upper and lower gland was defined as the section running through the widest transverse diameter of the prostate. All the sequences (T2W, DWI, DCE) were displayed on the screen of a workstation (iCAD Nashua, NH, USA) with automatic synchronization of the magnification and slice position. T2W, DWI, and each of the 3 parameters (K trans , k ep , and initial area under the gadolinium concentration curve) calculated from DCE MRI were scaled using a using a 3-point scale of 0 (benign or probably benign), 1 (intermediate) or 2 (malignant or probably malignant) ( Table 1 , Figure 1) . The values of the scores were added to define a T2W þ DW score (0-4), a T2 þ DCE score (0-8) and a T2W þ DW þ DCE score (0-10). All tumors involving more than one octant were assumed to have a volume 40.2 cm 3 . For tumors involving less than one octant, tumor size was estimated by measuring the crosssectional area (length Â width) multiplied by the thickness and number of cross sections occupied by the foci. 13 All tumors with a diameter o7 mm were considered to have volume o0.2 cm 3 (ref. 14) .
Pathological analysis
After fixation, the specimens were cut into 4-mm sections perpendicular to the posterior plane, labeled, embedded in paraffin and further sectioned to produce 5-mm wholemount sections that were stained with hematoxylin and eosin. Two pathologists (FB and AV) microscopically reviewed all samples. The total number of tumor foci and their location were recorded. An area of carcinoma was considered a separate focus, if it was separated by a low power field diameter (4.5 mm) from the nearest adjacent focus. Each tumor focus was graded according to the modified Gleason grading system. 15 Tumor size was estimated with the same method as that of MRI. Extracapsular cancer extension was also reported.
Measurements and statistical analysis
Each pathological slice was matched to the corresponding MR image and correlation analysis was carried out in each of the eight previously defined prostatic regions. 
Results
At final pathological examination, prostate cancer stage was pT2 in 54 cases and pT3 in 4 cases ( Table 2) . Gleason score was 46 in 13 (22%) patients. Of the 58, 50 (86%) RP specimens were involved with at least one tumor focus X0.2 cm 3 , and cancer involvement was bilateral in 20 cases (35%). Bilateral cancer involvement was related to an extension of the index tumor in 10 cases, and to multifocality in another 10. A total of 63 tumor foci X0.2 cm 3 were identified, including 48 in the PZ and 15 in the TZ. These tumor foci were involving a total of 95 prostate octants (95/464, 20%), 61 in the PZ and 34 in the TZ. Tumor foci involved less than an octant in 33/63 cases (52%) and more than an octant in the remaining 30 cases (30/63, 48%).
In the PZ (61 cancerous octants), T2W þ DWI, T2W þ DCE, and all three sequences combined performed significantly better than T2W alone to detect tumor foci 40.2 cm 3 (P ¼ 0.001, Figure 2a ). The best performance was obtained with all three sequences Figure 1 Posterior bilateral carcinoma of the peripheral zone in a 69-year-old man. PSA level was of 7.8 ng ml À1 . One left biopsy core showed 1-mm cancer involvement. Multiparametric magnetic resonance imaging (MRI) showed a mass like right hyposignal (T2W score of 2/2) and intermediate left hyposignal (T2W score of 1/2). Apparent diffusion coefficient (ADC) values were o1100 for both foci (diffusionweighted images (DWI) score 2/2); dynamic contrast enhanced (DCE) score was of 6/6 on both sides. Overall T2W þ DWI þ DCE score was of 10/10 on the right side, and 9/10 on the left side. A bilateral and Gleason score 7 (3 þ 4) carcinoma was identified on radical prostatectomy specimen. AUGC, area under the gadolinium concentration curve; Kep, rate constant; Ktrans, transfer constant; T2W, T2-weighted. combined, which performed significantly better than T2W þ DWI (P ¼ 0.006). T2W þ DCE and all three sequences combined performed better than T2W þ DWI, but the difference was not significant. According to the optimal cutoff score provided by the ROC curves (score 46/10), sensitivity and specificity of the three sequences combined for the detection of tumors 40.2 cm 3 were of 75 and 94%, respectively (Table 3) .
In the TZ (34 cancerous octants), the optimal MR combination for tumor detection was found to be T2W þ DWI, that performed significantly better than T2W alone and T2W þ DCE (P ¼ 0.02 and 0.005, respectively, Figure 2b ). T2W þ DWI performed also better than all three sequences combined, but the difference was not significant. Using the optimal cutoff provided by the ROC curve (score 41/4), sensitivity and specificity of T2W þ DWI for tumor detection were of 88 and 86%, respectively (Table 3) .
Using the optimal multiparametric combinations, as well as the optimal cutoffs for cancer detection in the PZ and TZ, at least one tumor focus X0.2 cm 3 was detected in 50/58 glands (86%). In the eight remaining prostate Figure 2 Graph a: Comparison of receiver operating characteristic (ROC) curves between T2-weighted (T2W) imaging alone, T2W þ dynamic contrast enhanced (DCE), T2W þ diffusion-weighted images (DWI), and all techniques combined for cancer detection in the peripheral zone. Graph b: Comparison of ROC curves between T2W imaging alone, T2W þ DCE, T2W þ DWI, and all techniques combined for cancer detection in the transition zone. 
Discussion
Our results confirmed that patients with suspected unilateral low-risk cancer can have high Gleason scores and large tumor volumes at final pathological examination. In our study, as much as a third of specimens harbored bilateral tumors of significant size. We found that multiparametric MRI could accurately predict those tumors. As already reported, both DWI and DCE improve T2W imaging accuracy in the PZ. 10, [16] [17] [18] Our results showed that the highest specificity was obtained with T2W þ DW imaging (98%), whereas sensitivity was increased by DCE imaging (82%) at the expense of a moderate loss of specificity (Table 2 ). In the TZ, however, our multiparametric MRI protocol failed to improve tumor detection. All three MRI sequences combined did not perform better than T2W alone, because the poor performance of DCE MRI lowered the overall accuracy. Reports on DCE MRI performance in the TZ are controversial. Some published results 14, 19 suggested indeed a potential value of DCE in the TZ, although other studies failed. 20, 21 In our series, ADC (provided by DW imaging) was the only parameter that improved performance when combined to T2W. These two parameters combined performed consequently better than all three MRI sequences altogether. Sensitivity of DWI for cancer detection in the TZ may be, however, altered because diffusion is restricted in both cancer and BPH tissue. 22 Substantial variations of DWI performance in the TZ were reported in literature, probably related to the absence of standard ADC cut-off value to differentiate cancer from benign tissue. 22, 23 Using the optimal multiparametric model in the PZ and TZ, most of the cancers underestimated by biopsies, PSA and clinical examination were correctly evaluated. We used a semi-quantitative estimation of intra-prostatic tumor spread by using the prostate octant as size referential. In all, 30 tumors were involving more than one octant and were considered to be large. Another 33 tumors were involving less than one octant and were defined as small. With this methodology, only one of the tumors involving more than one octant was missed by MRI. Of the 29 remaining large tumors identified on RP specimen, MRI accurately estimated tumor size in 77% of the cases. Tumor size was overestimated in only two of the tumors involving less than one octant. Moreover, bilateral cancer involvement (pathological stageXpT2c) was identified by MRI in 80% of cases.
These findings may be crucial for patients evaluation and counseling. An MRI showing no evidence of cancer in patients with unilateral low-risk prostate cancer could represent an additional criterion to indicate minimally invasive treatment (active surveillance, brachytherapy or focal therapy). In contrast, patients with visible tumor on MRI, especially in case of large volume or bilateral lesion, may be better candidates for aggressive treatment. Besides focality determination, targeting tumor foci with MRI may be of crucial help for the development of focal therapies such as cryoablation or photodynamic therapy. Tumor size estimation may also be of additional value for selecting patients into protocols of focal therapy. Additional studies are needed to further assess the value of multiparametric MRI as a therapeutic tool.
Our study has several limitations, the most obvious being the absence of tumor volume planimetric measurement on both MR images and histology. Another limitation is the absence of Gleason score evaluation with MRI, which is a prognostic factor as important as tumor intraprostatic spread. In this study, we did not correlate, as suggested by others, 24 the absolute ADC value with the presence of high Gleason score tumor foci. This would require a different DWI protocol with several b-values and was beyond the scope of this project.
Conclusions
In patients with low-risk disease and unilateral prostate cancer on biopsy, multiparametric MRI showed high specificity and sensitivity for tumor foci detection, resulting in an accurate estimation of tumor bilaterality (pathological stageXpT2c) in 80% of the cases. Therefore, multiparametric MRI may help to choose optimal treatment (minimally invasive or more aggressive therapy) in patients with favorable clinical features.
